Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kowa Launches Glanatec for Treatment of Glaucoma and Ocular Hypertension
December 3, 2014
- Xtandi Approved for Chemotherapy-Naïve Patients in Europe: Astellas
December 3, 2014
- Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
- A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
- Pralia Captures Top Spot in GP Market in October “Mind Share” Ranking
December 2, 2014
- Eisai Upgrades China to Independent Region with New Holding Firm
December 2, 2014
- Ferring to Launch Japan’s 1st Progestational Hormone Agent in ART Program on Dec. 5
December 2, 2014
- Eisai Files Lenvatinib for Approval in South Korea
December 2, 2014
- MTPC, Sawai Ink Final Pact on Transfer of Kashima Plant in April
December 2, 2014
- Daiichi Sankyo, UCB to Jointly Commercialize Epilepsy Drug Lacosamide
December 1, 2014
- Nippon Kayaku Rolls Out Remicade Biosimilar
December 1, 2014
- Novartis to Launch Stalevo Combination Tablets on Dec. 8
December 1, 2014
- Takeda to Transform Osaka Plant into Specialty Manufacturing Site for Leuplin
December 1, 2014
- Sandoz Launches Biosimilar of G-CSF Product Gran; Comarkets with Sawai
December 1, 2014
- Mochida Applies for Additional Indication of Social Anxiety Disorder for Lexapro
December 1, 2014
- EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
- MSD, Kyorin to Comarket Allergy Drug Desloratadine in Japan
November 28, 2014
- Novartis Files for Japan Approval of Equa-Metformin Combination Drug
November 28, 2014
- Kyowa Kirin Launches Sustained-Duration G-CSF Product G-Lasta
November 28, 2014
- Daiichi Sankyo Aims for No. 1 with Lixiana in Novel Oral Anticoagulant Market: Sales Division Head
November 28, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…